Introduction {#section1-1533033818796485}
============

Extracellular matrix (ECM) is a critical component of tumor microenvironment, and its remodeling is closely associated with cancer development such as cancer cell growth, survival, invasion, and motility.^[@bibr1-1533033818796485]^ Collagens are one of the major constituents of the ECM, which constitute up to 90% of the ECM.^[@bibr1-1533033818796485],[@bibr2-1533033818796485]^ In cancer biology, collagens are critical molecules regulating cell polarity, motility, and signaling.^[@bibr3-1533033818796485]^ Their deposition and stiffening are associated with facilitated metastasis of many solid tumors.^[@bibr4-1533033818796485]^

Prolyl 4-hydroxylase (P4 H) is an evolutionarily conserved enzyme, which can catalyze the formation of (2 S, 4 R)-4-hydroxyproline (Hyp).^[@bibr5-1533033818796485]^ (2 S, 4 R)-4-hydroxyproline is a critical posttranslational modification to ensure the proper 3-dimensional folding of newly synthesized procollagen chains into triple helix.^[@bibr5-1533033818796485]^ Therefore, P4 H is an essential enzyme to maintain collagen stability. Mammalian P4 H is a α2β2 tetramer in which the prolyl 4-hydroxylase alpha subunit (P4HA) is the enzymic substrate-binding domain.^[@bibr5-1533033818796485]^ Three isoforms of P4HA have been identified (*P4HA1*, *P4HA2*, and *P4HA3*), among which *P4HA1* is the most prevalent.^[@bibr5-1533033818796485],[@bibr6-1533033818796485]^ *P4HA2* is mainly expressed in osteoblasts, chondrocytes, and capillary endothelial cells.^[@bibr7-1533033818796485]^ In comparison, the expression of *P4HA3* is very low in normal fetal and adults tissues.^[@bibr6-1533033818796485]^

As the enzymic component of P4 H, dysregulated P4HA is associated with a series of pathological processes, including tumor initiation and progression.^[@bibr8-1533033818796485]^ P4HA1 and P4HA2 are critical for collagen deposition by breast cancer cells.^[@bibr4-1533033818796485],[@bibr9-1533033818796485]^ Their upregulation directly increases the invasiveness potential of the cancer cells and enhances metastasis to lymph nodes and lungs.^[@bibr4-1533033818796485],[@bibr9-1533033818796485]^ Increased expression of P4HA1 in prostate cancer can attenuate the expression of tumor suppressor FLRT3 but increase the expression of Matrix metalloproteinase 1 (MMP1) and Matrix metalloproteinase 2 (MMP2) to trigger invasion and metastasis.^[@bibr10-1533033818796485]^ Another recent study based on the bioinformatic analysis in The Cancer Genome Atlas (TCGA) found that *P4HA3* upregulation is highly correlated with genes representing ECM production in breast cancer, and higher *P4HA3* expression is associated with worse prognosis.^[@bibr11-1533033818796485]^

Extracellular matrix (ECM) remodeling also plays an essential role during the invasion and metastasis process of gastric cancer (GC).^[@bibr12-1533033818796485],[@bibr13-1533033818796485]^ Slug, which is also known as SNAI2, is a transcription factor that is involved in regulation of ECM in GC.^[@bibr14-1533033818796485],[@bibr15-1533033818796485]^ In this study, we found that *P4HA3* is significantly upregulated in GC than in normal tissues, and its upregulation is epigenetically activated by Slug. Also, we also observed that *P4HA3* upregulation is associated with GC metastasis and poor survival.

Materials and Methods {#section2-1533033818796485}
=====================

Bioinformatic Analysis Based on Data in the TCGA {#section3-1533033818796485}
------------------------------------------------

*P4HA3* RNA expression in gastrointestinal and some other solid tumors and in the corresponding normal tissues was examined using data from TCGA. In this database, 478 patients with GC having primary tumors, and 102 cases of normal solid tissues were included. Four hundred fifteen GC samples and 32 normal samples were subjected to RNA-seq analysis (IlluminaHiSeq UNC). The inclusion of patients and the availability of the genomic and pathological data were summarized in Supplemental Figure 1. Data analysis was performed using the FireBrowse (<http://firebrowse.org/>). Heatmap of *P4HA3* exon expression in patients with primary GC was reviewed using the UCSC Xena browser (<https://xenabrowser.net/>). The correlation between *P4HA3* RNA and *SNAI2* RNA expression was analyzed. Kaplan-Meier plots of 5-year and 10-year OS were generated by dividing the patients into high and low *P4HA1/P4HA2/P4HA3* expression groups according to median exon expression. The genes coexpressed with *P4HA3* in TCGA-Stomach Cancer (STAD) were identified by using cBioPortal for Cancer Genomics.^[@bibr16-1533033818796485],[@bibr17-1533033818796485]^

Data Mining in the Human Protein Atlas {#section4-1533033818796485}
--------------------------------------

P4HA3 expression in cancer tissues and the corresponding normal tissues were reviewed by data mining in Human Protein Atlas (<http://www.proteinatlas.org/>).^[@bibr18-1533033818796485]^ The images of P4HA3 immunohistochemistry (IHC) staining in GC tissues (N = 12) and normal stomach tissues were also downloaded from this database.

Data Mining in Kaplan-Meier Plotter {#section5-1533033818796485}
-----------------------------------

Association between *P4HA3* expression and overall survival (OS) or first progression-free survival (FPS) was examined using Kaplan-Meier plotter, which is an online database containing gene expression data and survival information of 1065 patients with GC.^[@bibr19-1533033818796485]^ The patients were grouped by median *P4HA3* expression. The hazard ratio (HR) with 95% confidence intervals (CIs) and log-rank *P* value were calculated. The number at risk is indicated below the survival curves.

Cell Culture and Transfection {#section6-1533033818796485}
-----------------------------

Poorly differentiated gastric adenocarcinoma cancer cell line MKN-45 and AGS cells were obtained from the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (Beijing, China). MKN-45 cells were cultured in a standard RPMI-1640, and AGS cells were grown in a standard Dulbecco\'s Modified Eagle Medium (DMEM) medium, each supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 1% (vol/vol) penicillin and streptomycin (10000 µg/mL) in a humidified chamber at 37°C in the presence of 5% CO~2~.

Lentiviral Slug and P4HA3 expression particle and the corresponding negative controls were purchased from GeneCopoeia (Rockville, Maryland). Lentiviral Slug short hairpin RNA (shRNA; sc-38393-V) and P4HA3 shRNA (sc-97000-V) and the corresponding negative controls were purchased from Santa Cruz Biotechnology (Santa Cruz, California). Cells were infected with the lentiviral particles in the presence of Polybrene.

Real-Time Quantitative Reverse Transcription PCR {#section7-1533033818796485}
------------------------------------------------

Briefly, total RNA in the cell samples were extracted using the Trizol Reagent (Invitrogen, Carlsbad, California, USA). Then, the complementary DNA (cDNA) was obtained by reverse transcription using the iScript cDNA Synthesis kit (Bio-Rad, Carlsbad, California) following the manufacturer's instructions. To quantify the expression of *P4HA3* messenger RNA (mRNA), qPCR was conducted using the gene-specific primers (forward, 5′-AAGTGGAGTACCGCATCAGC-3′ and reverse, 5′-TTGGTGACGTAGCATGGTCAA-3′) and the SYBR Select Master Mix (Applied Biosystems) in an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, California). RNA expression was normalized to the housekeeping gene GAPDH and was calculated used the 2^−ΔΔCT^ method.

Western Blotting {#section8-1533033818796485}
----------------

Cells were harvested and lysed in an Radioimmunoprecipitation assay (RIPA) buffer. Protein lysates of 30 µg were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by western blot analysis. The antibodies used were as follows: rabbit monoclonal anti-Slug (1:200, sc-166476, Santa Cruz, Cambridge, UK), anti-P4HA3 (1:1000, ab101657, Abcam), and anti-β-actin (1:1000, ab3280, Abcam, Cambridge, UK). Antigen--antibody complexes were detected by electrochemiluminiscence Western blotting detection reagent (GE Healthcare, Marlborough, Massachusetts). Band densitometry was performed using ImageJ software (version 1.48, Bio-Rad, Hercules, California, USA).

Transwell Assay {#section9-1533033818796485}
---------------

Transwell assay was conducted using a Matrigel invasion chamber (BD Bioscience, San Jose, California) in a 24-well cell culture plate following the manufacturer's instruction. Briefly, MKN-45 and AGS cells with P4HA3 overexpression or knockdown were seeded into chamber inserts containing an 8-μm pore size membrane with a thin layer matrigel matrix, with 500 μL serum-free RPMI-1640 or DMEM medium. The bottom of the well was filled with 700 μL RPMI-1640 or DMEM medium with 20% FBS. Forty-eight hours later, cells invaded to the lower surface of the membrane were fixed, while the noninvading cells on the upper surface were removed. The invaded cells were stained with 0.1% Crystal violet, and the number was then determined for 3 independent fields under a microscope.

Wound Healing Assay {#section10-1533033818796485}
-------------------

Briefly, MKN-45 and AGS cells were cultured in 6-well plates and were infected with lentiviral P4HA3 shRNA particles or the negative controls. Twenty-four hours later, confluent cell monolayers were manually wounded by scraping the cells with a 200-μL pipette tip. Wound images were taken at 0 and 24 hours after the scratch. The wound areas were measured using the ImageJ software (n = 3).

ChIP-qPCR {#section11-1533033818796485}
---------

The promoter sequence of P4HA3 was obtained from GeneCopoeia (\>HPRM41923, NM_001288748, Supplemental Figure). The possible Slug-binding sites in the promoter region were predicted using the JASPAR Database (<http://jaspar.genereg.net/>). ChIP assay was conducted using the Upstate-ChIP Assay Kit (Upstate, Lake Placid, New York) according to the manufacturer's instructions. Briefly, equal aliquots of chromatin supernatants from MKN-45 or AGS cells were subjected to immunoprecipitation with 1 μg of normal goat immunoglobulin G (IgG) or anti-Slug overnight at 4°C with rotation. After reverse cross-link of protein/DNA complexes to free DNA, the ChIP-enriched DNA was analyzed by quantitative polymerase chain reaction (qPCR) using the ABI 7900HT sequence detection system and SYBR green master mix. Primers used for *P4HA3* promoter were left, 5′-CCATTGCATATTGCACAACC-3′and right, 5′-CAGGCAATGTTCATTCATGC-3′. The location of the primers was indicated in [Figure 1F](#fig1-1533033818796485){ref-type="fig"}. The validated nonspecific primers (left, 5′-TTTTACGGGGCAACTACGGC-3′ and right, 5′-CAGTGGCATCCATTAGCAGGTC-3′) were used as a negative control.

![*P4HA3* is epigenetically activated by Slug in gastric cancer. A, Regression analysis of the expression between *P4HA3* and *SNAI2* in Cancer Genome Atlas-Stomach Cancer (TCGA-STAD). B-C, Quantitative polymerase chain reaction (qPCR) analysis of *P4HA3* messenger RNA (mRNA) expression in MKN-45 (B) and AGS (C) cells 36 hours after infection of lentiviral Slug expression particles (B) or lentiviral Slug short hairpin RNA (shRNA) (C). D-E, Western blot analysis of Slug and P4HA3 expression in MKN-45 (D) and AGS (E) cells 48 hours after infection of lentiviral Slug expression particles (D) or lentiviral Slug shRNA (E). F, Predicted high score Slug binding sites in the *P4HA3* promoter region. G-H, Fold-enrichment of Slug binding at the *P4HA3* promoter relative to the background in MKN-45 (G) and AGS (H) cells was measured by ChIP-qPCR. The primer set for chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) is indicated in figure F. Upon normalization to GAPDH, results were expressed as n-fold compared to IgG. I, The luciferase reporter constructs carrying intact or truncated *P4HA3* promoter sequences were introduced into HEK-293 cells preinfected with lentiviral Slug expression particles. Luciferase activity was measured 24 hours posttransfection. PWM indicates position weight matrix. \*\*, *P \<* .01.](10.1177_1533033818796485-fig1){#fig1-1533033818796485}

Dual Luciferase Assay {#section12-1533033818796485}
---------------------

*P4HA3* promoter has 1318 nucleotides, including 1254 nucleotides upstream and 63 nucleotides downstream of the transcriptional start site site (Supplemental Figure). To further verify the predicted binding sites and the effect of Slug on transcription activity, the intact promoter sequence (−1253/+63) and 4 truncated promoter sequences, including −800/+63, −600/+63, −400/+63, and −400/+63, were PCR amplified from the *P4HA3* promoter plasmid. Then, the fragments were cloned into the site between *XhoI* and *Hind III* of the pGL3-basic luciferase reporter vector, respectively. HEK-293 cells preinfected with lentiviral Slug expression particles were plated into 12-well plates (1×10^5^ cells/well) and were cotransfected the with 1.5 μg reconstructed luciferase plasmids or the empty control and 0.05 μg phRL-TK by using Superfectin (Qiagen, Valencia, California). Twenty-four hours after transfection, cells were lysed, and the luciferase activity was assessed using the dual-luciferase reporter assay system (Promega, Madison, Wisconsin) with a luminometer (Promega). The luciferase activity was normalized to the activity of renilla luciferase.

Statistical Analysis {#section13-1533033818796485}
--------------------

Data were reported as means (standard deviation) . The group difference was performed by 2-tailed Student *t* test or analysis of variance with Student-Newman-Keuls test as a post hoc test. Log-rank test was performed to detect the difference between the survival curves. Regression analysis was performed to identify the correlation between the expression of *P4HA3* and *SNAI2* and among *P4HA1/P4HA2/P4HA3*. *P* \< .05 was considered statistically significant.

Results {#section14-1533033818796485}
=======

*P4HA3* is Significantly Upregulated in Gastric Cancer Tissues than in Normal Controls {#section15-1533033818796485}
--------------------------------------------------------------------------------------

By data mining in TCGA, we first characterized *P4HA3* expression in some solid tumors ([Figure 2A](#fig2-1533033818796485){ref-type="fig"}). Results showed that *P4HA3* expression is significantly higher in GC tissues (N = 415) than in normal controls (N = 32; [Figure 2A](#fig2-1533033818796485){ref-type="fig"}). Then, we examined *P4HA3* expression at the protein level by data mining in the Human Protein Atlas. In normal gastric tissues, the P4HA3 expression is usually not detectable by IHC staining ([Figure 2B and C](#fig2-1533033818796485){ref-type="fig"}). However, among 12 cases of GC examined, 7 cases have detectable P4HA3 expression ([Figure 2B](#fig2-1533033818796485){ref-type="fig"}), mainly in cytoplasma and membrane ([Figure 2C](#fig2-1533033818796485){ref-type="fig"}).

![*P4HA3* is significantly upregulated in gastric cancer tissues than in normal controls. A, *P4HA3* messenger RNA (mRNA) expression in some solid tumors. Box plots were obtained by data mining in FireBrowse. B, P4HA3 IHC staining summary in some cancers and the corresponding normal tissues. C, Representative images of P4HA3 IHC staining in gastric cancer tissues and normal stomach tissues. Data and images were obtained from the Human Protein Atlas (<http://www.proteinatlas.org/ENSG00000149380-P4HA3/tissue/stomach> and <http://www.proteinatlas.org/ENSG00000149380-P4HA3/pathology/tissue/stomach+cancer>).](10.1177_1533033818796485-fig2){#fig2-1533033818796485}

*P4HA3* is Epigenetically Activated by Slug in Gastric Cancer {#section16-1533033818796485}
-------------------------------------------------------------

To explore the mechanism of elevated *P4HA3* expression in GC, we screened the genes coexpressed with *P4HA3* in TCGA-STAD and observed that *SNAI2* (encoding Slug) is highly coexpressed with *P4HA3* (Pearson *r* = 0.70, [Figure 1A](#fig1-1533033818796485){ref-type="fig"}). Since Slug is a transcription factor that can modulate multiple genes in GC, we further studied whether it has a regulative effect on *P4HA3* expression. In both MKN-45 and AGS cells, Slug overexpression significantly increased *P4HA3* expression at the mRNA and protein level ([Figure 1B and D](#fig1-1533033818796485){ref-type="fig"}). Slug shRNA reduced around 54% Slug expression in MKN-45 cells while inhibited about 72% Slug expression in AGS cells ([Figure 1E](#fig1-1533033818796485){ref-type="fig"}). Consecutively, Slug shRNA resulted in over 70% of *P4HA3* mRNA inhibition ([Figure 1C](#fig1-1533033818796485){ref-type="fig"}) and over 35% of P4HA3 protein inhibition in both MKN-45 and AGS cells ([Figure 1E](#fig1-1533033818796485){ref-type="fig"}). To further explore the underlying mechanisms, the promoter sequence of *P4HA3* (Supplemental Figure 2) was subjected to the prediction of Slug-binding sites. Results showed that there are 2 possible Slug-binding sites in the promoter of *P4HA3* ([Figure 1F](#fig1-1533033818796485){ref-type="fig"}). To verify the prediction, ChIP-qPCR was first performed with primers designed near the predicted binding sites. Results confirmed that the DNA samples immunoprecipitated by Slug antibody from MKN-45 and AGS cells had a significantly higher enrichment of *P4HA3* promoter fragments than the controls ([Figure 1G and H](#fig1-1533033818796485){ref-type="fig"}). To further validate the direct binding and associated activating effect, luciferase reporter constructs carrying truncated *P4HA3* promoter sequences were generated. The dual luciferase assay showed that Slug overexpression significantly increased the luciferase activity of the reporter carrying intact *P4HA3* promoter sequence ([Figure 1I](#fig1-1533033818796485){ref-type="fig"}). In addition, truncating anyone of the 2 predicted Slug-binding sites resulted in significant decrease in luciferase activity in HEK-293 cells preinfected with lentiviral Slug expression particles ([Figure 1I](#fig1-1533033818796485){ref-type="fig"}). These findings suggest that Slug can efficiently bind to the *P4HA3* promoter and increase its transcription.

*P4HA3* Upregulation is Associated With Gastric Cancer Metastasis {#section17-1533033818796485}
-----------------------------------------------------------------

By using the cBioPortal for Cancer Genomics, we found that *MMP2, MMP14*, and *MMP19* are highly coexpressed with *P4HA3* in TCGA-STAD ([Table 1](#table1-1533033818796485){ref-type="table"}). Some collagen genes, such as *COL6A3, COL1A2, COL3A1, COL5A2, COL5A1, COL8A1, COL1A1, COL12A1*, and *COL15A1*, are also highly coexpressed with *P4HA3* ([Table 1](#table1-1533033818796485){ref-type="table"}). These findings imply that P4HA3 might be related to ECM remodeling in GC. By comparing the expression of *P4HA3* between lymph nodal positive and negative cases, we failed to identify significant association ([Figure 3A](#fig3-1533033818796485){ref-type="fig"}). However, by comparing its expression between the intestinal and diffuse histological subtypes, we found that the more malignant diffuse subtype had significantly higher *P4HA3* expression compared to the intestinal subtype ([Figure 3B](#fig3-1533033818796485){ref-type="fig"}). Then, we further assessed the association between *P4HA3* and GC metastasis. By comparing *P4HA3* exon expression in patients with metastasis (M1, N = 27) and without metastasis (M0, N = 367), we observed that 2 exons are significantly upregulated in M1 cases than in M0 cases ([Figure 4A and B](#fig4-1533033818796485){ref-type="fig"}). Then, we tried to further identify the functional role of *P4HA3* in cell motility and invasion. Both MKN-45 and AGS cells were transfected with *PH4A3* lentiviral expression particles or shRNA ([Figure 4C](#fig4-1533033818796485){ref-type="fig"}). Results of wound healing assay and transwell assay showed that *P4HA3* overexpression significantly enhanced motility and invasion of the cancer cells ([Figure 4D and E](#fig4-1533033818796485){ref-type="fig"}), while *P4HA3* inhibition substantially reduced their motility and invasion potential ([Figure 4F and G](#fig4-1533033818796485){ref-type="fig"}).

###### 

MMP and Collagen Genes Coexpressed With *P4HA3* in TCGA-STAD.

![](10.1177_1533033818796485-table1)

  Gene Symbol   Cytoband       Pearson Score   Spearman Score
  ------------- -------------- --------------- ----------------
  *MMP2*        16q12.2        0.82            0.76
  *MMP19*       12q14          0.66            0.64
  *MMP14*       14q11.2        0.65            0.77
  *COL6A3*      2q37           0.8             0.79
  *COL1A2*      7q22.1         0.74            0.88
  *COL3A1*      2q31           0.73            0.86
  *COL5A2*      2q14-q32       0.73            0.84
  *COL5A1*      9q34.2-q34.3   0.69            0.84
  *COL8A1*      3q12.3         0.69            0.79
  *COL1A1*      17q21.33       0.64            0.84
  *COL12A1*     6q12-q13       0.62            0.76
  *COL15A1*     9q21-q22       0.62            0.58
  *COL14A1*     8q23           0.56            0.49
  *COL18A1*     21q22.3        0.56            0.65
  *COL6A1*      21q22.3        0.55            0.58
  *COL6A2*      21q22.3        0.54            0.6
  *COL16A1*     1p35-p34       0.5             0.63

Abbreviations: MMP: Matrix metallopeptidase; TCGA-STAD, Cancer Genome Atlas-Stomach Cancer.

^a^ Results were obtained from cBioPortal for Cancer Genomics.

![*P4HA3* expression is higher in diffuse gastric cancer compared to intestinal gastric cancer. A-B, Comparison of *P4HA3* expression between lymph nodal positive/negative cases (A) and between 2 histological subtypes (diffuse and intestinal) of gastric cancer (B), according to the Lauren classification.](10.1177_1533033818796485-fig3){#fig3-1533033818796485}

![*P4HA3* upregulation is associated with gastric cancer metastasis. A, Heatmap of *P4HA3* exon expression in Cancer Genome Atlas-Stomach Cancer (TCGA-STAD). B, *P4HA3* exon expression in patients with metastasis (M1, N = 27) and without metastasis (M0, N = 367). C, Western blot analysis of P4HA3 expression in MKN-45 and AGS cells 48 hours after infection of lentiviral P4HA3 expression particles or lentiviral shRNA. D-G, Quantitative results of wound healing assay (D and F) and transwell assay (E and G) that were conducted 48 hours after indicating infection in MKN-45 and AGS cells. The relative wound areas at 24 hours compared to 0 hours after scratch were calculated to reflect the speed of wound healing. The relative proportion of invaded cells in P4HA3 overexpression/shRNA groups compared to Vector/shNC groups was calculated to reflect the capability of cell invasion. \*\*, *P \<* .01.](10.1177_1533033818796485-fig4){#fig4-1533033818796485}

*P4HA3* but not *P4HA1/P4HA2* Upregulation is Associated with Poor Survival {#section18-1533033818796485}
---------------------------------------------------------------------------

Via analyzing the survival outcomes of patients with GC in TCGA-STAD, we observed that high *P4HA3* exon expression is associated with significantly worse 5-year and 10-year OS (*P =* .007 and .009, respectively; [Figure 5A and B](#fig5-1533033818796485){ref-type="fig"}). Following data mining in Kaplan-Meier plotter also showed that high *P4HA3* expression is associated with unfavorable OS (hazard ratio \[HR\]: 1.54, 95% confidence interval \[CI\]: 1.23-1.93, *P \<* .001) and FPS (HR: 1.64, 95% CI: 1.29-2.1, *P \<* .001; [Figure 5C and D](#fig5-1533033818796485){ref-type="fig"}). Since P4HA1, P4HA2, and P4HA3 have similar functions, we also examined the association between *P4HA1/P4HA2* expression and OS in patients with GC. In TCGA-STAD, no significant correlation was observed among *P4HA1/P4HA2/P4HA3* ([Figure 5E and F](#fig5-1533033818796485){ref-type="fig"}). Log-rank test of Kaplan-Meier curves also indicated that there is no significant difference in survival between high and low *P4HA1* or *P4HA2* exon expression groups ([Figure 6A-D](#fig6-1533033818796485){ref-type="fig"}).

![*P4HA3* upregulation is associated with poor survival of patients with gastric cancer. A-B, Kaplan-Meier curves of 3-year (A) and 5-year (B) overall survival of patients with gastric cancer grouped by high or low *P4HA3* expression (median splitting) in Cancer Genome Atlas-Stomach Cancer (TCGA-STAD). Survival curves were generated by using the UCSC Xena. C-D, Kaplan-Meier curves of overall survival (C) and FPS (D) of patients with gastric cancer grouped by high or low *P4HA3* expression (median splitting) in Kaplan-Meier Plotter. E-F, Heatmap of *P4HA1/P4HA2/P4HA3* expression in Cancer Genome Atlas-Stomach Cancer (TCGA-STAD) (E) and correlation matrix (F) showing their correlations.](10.1177_1533033818796485-fig5){#fig5-1533033818796485}

![*P4HA1* or *P4HA2* expression is not associated with the survival of gastric cancer. A-D, Kaplan-Meier curves of 3-year (A and C) and 5-year (B and D) overall survival of patients with gastric cancer grouped by high and low *P4HA1* (A-B) or *P4HA2* (C-D) expression (median splitting) in Cancer Genome Atlas-Stomach Cancer (TCGA-STAD). Survival curves were generated by using the UCSC Xena.](10.1177_1533033818796485-fig6){#fig6-1533033818796485}

Discussion {#section19-1533033818796485}
==========

As the enzymic active site of P4 H, the expression profile and functional role of *P4HA3* in GC have not been explored. Although *P4HA3* expression is usually low in normal human tissues, its catalytic properties are very similar to those of P4HA1 and P4HA2.^[@bibr6-1533033818796485]^ In this study, via data mining in TCGA-STAD, we found that *P4HA3* RNA is significantly upregulated in GC than in normal stomach tissues. In the Human Protein Atlas, we observed that P4HA3 is not detectable by IHC staining in normal stomach tissues, but it has weak staining in 7 of 12 GC tissues. These findings suggest that *P4HA3* might be activated in some GC cases.

Via bioinformatic prediction, we found that Slug is coexpressed with *P4HA3* and has 2 possible binding sites in the *P4HA3* promoter. In fact, Slug is usually upregulated in GC^[@bibr20-1533033818796485]^ and confers increased potential of motility and invasion to the cancer cells.^[@bibr21-1533033818796485]^ In cancer biology, Slug can be either transcription suppressor or activator, depending on specific cancers and environment. Traditionally, Slug can negatively regulate the transcription of multiple genes by binding to E-box motifs in their promoters, such as E-cadherin^[@bibr22-1533033818796485]^ and Phosphatase and tensin homolog (PTEN).^[@bibr23-1533033818796485]^ Recent studies found that it can activate the transcription of hexokinase-2 and MMP1 by binding to their respective promoters in breast cancer^[@bibr24-1533033818796485],[@bibr25-1533033818796485]^ and can also activate *ZEB1* expression in melanoma via promoter binding.^[@bibr26-1533033818796485]^ In GC, increased Slug expression has well-characterized oncogenic properties and also confers malignant behaviors to the cancers. Slug-induced epithelial-to-mesenchymal transition results in enhanced GC cell invasion and metastasis.^[@bibr27-1533033818796485],[@bibr28-1533033818796485]^ Slug-positive gastric tumors are at a worse stage and also associated with a higher risk of lymph node metastasis, lymphatic invasion, and venous invasion than the tumors with negative Slug expression.^[@bibr20-1533033818796485],[@bibr29-1533033818796485]^ However, its downstream regulation in GC has not been fully understood. In this study, we found that Slug can transactivate *P4HA3* expression in GC, which is a novel epigenetic regulative effect of Slug in GC.

In this current study, via bioinformatic analysis, we observed that 2 *P4HA3* exons are significantly upregulated in M1 cases than in M0 cases. However, we failed to identify any significant association between *P4HA3* and lymphatic invasion. Very limited studies reported the functional role of P4HA3 in cancer,^[@bibr11-1533033818796485]^ and no studies have explored the role of P4HA3 in colorectal cancer. The only known clue is that P4HA3 is a collagen-modifying enzyme causing 4-hydroxylation of prolines,^[@bibr6-1533033818796485]^ and it is the only *P4HA* gene that seems to be selectively expressed in the stroma of breast tumors.^[@bibr11-1533033818796485]^ Since *P4HA3* is a gene modulating collagen fibres, we then tried to evaluate its contribution to collagen deposition in GC and association with tumor metastasis. Among *P4HA3* coexpressed MMPs, MMP2 is able to degrade type IV collagen, and its upregulation is associated with ECM remodeling, vascular invasion, and metastasis of gastric cancer.^[@bibr30-1533033818796485][@bibr31-1533033818796485]--[@bibr32-1533033818796485]^ MMP14 also had a significant correlation with lymph node metastasis and tumor stage^[@bibr33-1533033818796485]^ and can also promote vascular invasion via enhancing the expression of vascular endothelial growth factor .^[@bibr34-1533033818796485]^ In fact, extramural vascular invasion independently predicts metastases and poor survival in patients with GC.^[@bibr35-1533033818796485],[@bibr36-1533033818796485]^ Therefore, we hypothesized that *P4HA3* upregulation might be associated with distant metastasis via enhancing extramural vascular invasion of GC. Among *P4HA3* coexpressed collagens, *COL6A3, COL1A1, COL1A2, COL3A1, COL5A1* and *COL5A2* are known upregulated genes in GC.^[@bibr37-1533033818796485],[@bibr38-1533033818796485]^ *COL1A2* expression level is significantly associated with the histological type and lymph node status.^[@bibr39-1533033818796485],[@bibr40-1533033818796485]^ *COL5A1* is among the signature genes associated with prognosis of GC.^[@bibr38-1533033818796485]^ In *in vitro* studies using MKN-45 and AGS cells, we confirmed that *P4HA3* upregulation could enhance cell motility and invasiveness. Therefore, we infer that *P4HA3* is among the network regulating metastasis of GC by modulating ECM remodeling and vascular invasion. In the future, it is meaningful to further investigate the detailed functional role of P4HA3 in ECM remodeling, especially in ECM production or desmoplastic reaction and extramural vascular invasion.

*P4HA3* upregulation might predict poor prognosis in breast cancer.^[@bibr11-1533033818796485]^ In this study, we further examined the association between *P4HA3* expression and survival of patients with GC. Based on data mining in 2 large databases, we observed that high *P4HA3* expression is associated with unfavorable survival. However, no significant difference in survival was found between high and low *P4HA1* or *P4HA2* exon expression groups. These findings suggest that deregulated *P4HA3* might be a specific indicator of poor survival of GC.

Conclusion {#section20-1533033818796485}
==========

Based on findings above, we infer that *P4HA3* is significantly upregulated in GC than in normal tissues and its upregulation is epigenetically activated by Slug. *P4HA3* deregulation is associated with enhanced metastasis and poor survival of GC.
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cDNA

:   complementary DNA

CI

:   confidence intervals

ECM

:   extracellular matrix

FPS

:   first progression-free survival

FBS

:   fetal bovine serum

HR

:   hazard ratio

IHC

:   immunohistochemistry

mRNA

:   messenger RNA

OS

:   overall survival

P4H

:   Prolyl 4-hydroxylase

Hyp

:   (2 S, 4 R)-4-hydroxyproline

P4HA

:   prolyl 4-hydroxylase alpha

qPCR

:   quantitative polymerase chain reaction

STAD

:   Stomach Cancer

shRNA

:   short hairpin RNA

TCGA

:   Cancer Genome Atlas
